补蔻补虚汤治疗溃疡性结肠炎的临床效果  

Clinical effect of bukoubuxu decoction on ulcerative colitis and its regulatoryeffect on inflammatory mediator and immune function

作　　者：李慧[1] 张萍[1] 徒文静 葛超[1] LI Hui;ZHANG Ping;TU Wenjing;GE Chao(Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing 210029,China)

机构地区：[1]江苏省中医院,江苏南京210029

出　　处：《西部医学》2024年第7期1007-1011,共5页Medical Journal of West China

基　　金：教育部人文社会科学研究青年基金项目(19YJCZH147)。

摘　　要：目的探讨补蔻补虚汤治疗溃疡性结肠炎的临床效果及对炎性介质与免疫功能的调节作用。方法选取2019年4月—2021年7月我院收治的溃疡性结肠炎患者100例,随机分为对照组(n=50)和观察组(n=50)。对照组口服美沙拉嗪缓释片和双歧杆菌,直肠给予美沙拉嗪栓,静脉滴注丙氨酰谷氨酰胺注射液(多蒙特)和复方氨基酸注射液,连续治疗2周。观察组在对照组的基础上给予补蔻补虚汤,每日一剂,汤汁400 mL,分早晚两次服用,连续服用2个月。分别于治疗前及治疗后,采用酶联免疫吸附法(ELISA)测定患者血浆中D-乳酸水平及血清中白介素10(IL-10)、IL-6和肿瘤坏死因子(TNF-α)水平。采用高效液相色谱法测定尿液样品中的乳果糖和甘露醇水平,并测定乳果糖/甘露醇值(L/M值)。评估患者临床疗效和中医证候积分。评价患者肠黏膜组织。采用ELISA测定患者血清中上皮细胞膜结合黏液素1(MUC1)水平,采用ELISA双抗体夹心法测定患者血清中单核细胞趋化蛋白1(MCP-1)水平。结果观察组和对照组的临床治疗总有效率分别为94.00%和76.00%,差异具有统计学意义(P<0.05)。治疗前,两组中医症候积分水平相比无统计学意义(P>0.05);治疗后,两组中医症候积分水平均升高,且观察组中医症候积分显著低于对照组(P<0.05);治疗前,两组患者D-乳酸和尿L/M水平相比无统计学意义(P>0.05);治疗后,两组D-乳酸和尿L/M水平显著降低,且观察组D-乳酸和尿L/M水平显著低于对照组(P<0.05);治疗前,两组患者血清炎性因子IL-6、IL-10和TNF-α水平相比无统计学意义(P>0.05);治疗后,两组IL-6、IL-10和TNF-α水平显著降低,且观察组IL-6、IL-10和TNF-α水平均显著低于对照组(P<0.05);治疗前,两组患者Geboes指数相比无统计学意义(P>0.05);治疗后,两组Geboes指数显著降低,且观察组Geboes指数显著低于对照组(P<0.05)。结论补蔻补虚汤治疗轻、中度溃疡性结肠炎的临床�Objective To study the clinical effect of Bukoubuxu Decoction on ulcerative colitis and its regulating effect on inflammatory mediators and immune function.Methods 100 patients with ulcerative colitis admitted to our hospital from April 2019 to July 2021 were randomly divided into the control group(n=50)and the observation group(n=50).The control group was given mesalazine sustained-release tablets and Bifidobacterium orally,mesalazine suppository rectally,alanyl glutamine injection(Domonte)and compound amino acid injection intravenously for 2 weeks.On the basis of observation and control group,Bukoubuxu Decoction was given once a day,400mL of soup,twice in the morning and evening,for 2 months.The levels of D-lactic acid in plasma and interleukin-10(IL-10),IL-6 and tumor necrosis factor(TNF-α)in serum were measured by enzyme-linked immunosorbent assay before and after treatment respectively.The levels of fructose and Gan Lu alcohol in urine samples and lactulose/mannitol value(L/M value)were determined by HPLC.Evaluated the clinical efficacy and TCM syndrome score of patients.Evaluated the intestinal mucosa of patients.The level of MUC1 in patients'serum was determined by enzyme-linked immunosorbent assay(ELISA),and the level of MCP1 in patients'serum was determined by enzyme-linked immunosorbent assay(ELISA)and double antibody sandwich method.Results The total effective rates of clinical treatment in the observation group and the control group were 94.00%and 76.00%respectively(P<0.05).After treatment,the TCM symptom score,D-lactic acid and urine L/M levels,IL-6,IL-10 and TNF-αlevels,Geboes index,serum MUC1 and MCP-1 levels in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Bukoubuxu Decoction has remarkable clinical effect in treating mild-moderate ulcerative colitis,which can significantly improve the inflammatory reaction of patients and increase the immune function.

关 键 词：补蔻补虚汤 溃疡性结肠炎 炎性 免疫功能 临床效果 

分 类 号：R574.62[医药卫生—消化系统]